Neither antibody to a group B streptococcal conjugate vaccine nor the vaccine itself is teratogenic in rabbits

Human Vaccines

Volumn 4, Issue 6, 2008, Pages 435-443

  Paoletti, Lawrence C ^a   Gultormsen, Hilde Kari ^a   Christian, Mildred S ^b   Hoberman, Alan M ^c   McInnes, Pamela ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Argus International Inc   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Developmental toxicity study; Glycoconjugate vaccines; Group B streptococcus; Serotype III

Indexed keywords

BACTERIAL VACCINE; GROUP B STREPTOCOCCUS TYPE II CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE; GROUP B STREPTOCOCCUS TYPE III CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE; NONSTEROID ANTIINFLAMMATORY AGENT; SODIUM CHLORIDE; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; GROUP B STREPTOCOCCAL TYPE III CAPSULAR POLYSACCHARIDE TETANUS TOXOID VACCINE; GROUP B STREPTOCOCCAL TYPE III CAPSULAR POLYSACCHARIDE-TETANUS TOXOID VACCINE; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CHILL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MANUFACTURE; DRUG POTENCY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETAL WELL BEING; FETUS DEVELOPMENT; FETUS GROWTH; FETUS MALFORMATION; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALAISE; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PREGNANCY OUTCOME; QUANTITATIVE ANALYSIS; RABBIT; SEX RATIO; STREPTOCOCCUS AGALACTIAE; TERATOGENICITY; TOXICITY TESTING; ANIMAL; BACTERIAL MEMBRANE; BLOOD; BREEDING; CONGENITAL DISORDER; DRUG EFFECT; FETUS; IMMUNOLOGY; MALE; MOUSE; PATHOLOGY; PREGNANCY; RANDOMIZATION; SURVIVAL;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL CAPSULES; CONGENITAL ABNORMALITIES; FEMALE; FETUS; IMMUNOGLOBULIN G; MALE; MICE; PREGNANCY; PREGNANCY, ANIMAL; RABBITS; RANDOM ALLOCATION; SEX RATIO; STREPTOCOCCAL VACCINES; SURVIVAL ANALYSIS;

EID: 56149094911     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.6.6178     Document Type: Article

References (34)

1. Edwards MS, Baker CJ. Streptococcus agalactiae (Group B Streptococcus). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Disease. Philadelphia: Elsevier 2005.
2. Edwards MS, Baker CJ. Group B streptococcal infections. In: Remington J, Klein J, eds. Infectious diseases of the fetus and newborn infant. Philadelphia: W.B. Saunders 2001; 1091-156.
3. Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976; 294:753-6.
4. Paoletti LC. Academic pursuits of vaccines against group B Streptococcus. In: Ellis RW, Brodeur BR, eds. New Bacterial Vaccines. Georgetown, TX: Eureka.com and Kluwer Academic/Plenum 2003; 174-91.
5. Baker CJ, Rench MA, Edwards MS, Carpenter RJ, Hays BM, Kasper DL. Immunization of pregnant women with a polysaccharide vaccine of group B Streptococcus. N Engl J Med 1988; 319:1180-220.
6. Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Broom CV, Wegner JD. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993; 269:221-6.
7. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Takala A, Kayhty H, Karma P, Kohberger R, Siber G, Makela PH. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344:403-9.
8. Kasper DL, Paoletti LC, Wessels MR, Guttormsen HK, Carey VJ, Jennings HJ, Baker CJ. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 1996; 98:2308-14.
9. Paoletti LC, Pinel J, Johnson KD, Reinap B, Ross RA, Kasper DL. Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII. J Infect Dis 1999; 180:892-5.
10. Paoletti LC. Potency of clinical group B streptococcal conjugate vaccines. Vaccine 2001; 19:2118-26.
11. Christian MS, Hoberman AM, Smith THF. Dosage-range study of the teratogenic potential of suspensions of trinitrofluorenone (TNF) administered orally to New Zealand White rabbits. Toxicologist 1982; 2:40.
12. Feussner EL, Lightkep GE, Hennesy RA, Hoberman AM, Christian MS. A decade of rabbit fertility data: study of historical control animals. Teratology 1992; 46:349-65.
13. Christian MS, McCarty RJ, Cox-Sica DK, Cao CP. Recent increases of skull, lung and rib alterations in vehicle control New Zealand White rabbits. J Amer Col Toxicol 1987; 6:562.
14. U.S. Food and Drug Administration. International conference on Harmonization; Guidelines on detection of toxicity to reproduction for medicinal purposes. Federal Register 1994; 59:183.
15. Baker CJ, Rench MA, Fernandez M, Paoletti LC, Kasper DL, Edwards MS. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis 2003; 188:66-73.
16. Paoletti LC, Rench MA, Kasper DL, Molrine D, Ambrosino D, Baker CJ. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines. Infect Immun 2001; 69:6696-701.
17. Paoletti LC, McInnes P, eds. Vaccines: From Concept to Clinic. A guide to the development and clinical testing of vaccines for human use. Boca Raton, FL: CRC Press 1999.
18. Stratton KR, Durch JS, Lawrence RS, eds. Institutes of Medicine (U.S.). Committee to study priorities for vaccine development. Vaccines for the 21st century: a tool for decision making. Washington, D.C.: National Academy Press 2000.
19. Wessels MR, Paoletti LC, Guttormsen HK, Michon F, D'Ambra AJ, Kasper DL. Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy. Infect Immun 1998; 66:2186-92.
20. Bolgiano B, Mawas F, Burkin K, Crane DT, Saydam M, Rigsby P, Corbel MJ. A retrospective study on the quality of Haemophilus influenzae type b vaccines used in the UK between 1996 and 2004. Human Vacc 2007; 3:176-82.
21. Rodewald AK, Onderdonk AB, Warren HB, Kasper DL. Neonatal mouse model of group B streptococcal infection. J Infect Dis 1992; 166:635-9.
22. Paoletti LC, Pinel J, Kennedy RC, Kasper DL. Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate. J Infect Dis 2000; 181:653-8.
23. Davies JK, Paoletti LC, McDuffie RS, Madoff LC, Lee S, Eskens J, Gibbs RS. A randomized trial of conjugated group B streptococcal type Ia vaccine in a rabbit model of ascending infection. Am J Obstet Gynecol 1999; 181:803-8.
24. Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 2003; 21:3468-72.
25. Wessels MR, Paoletti LC, Kasper DL, DiFabio JL, Michon F, Holme K, Jennings HJ. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest 1990; 86:1428-33.
26. Guttormsen HK, Baker CJ, Edwards MS, Paoletti LC, Kasper DL. Quantitative determination of antibodies to type III group B streptococcal polysaccharide. J Infect Dis 1996; 173:142-50.
27. Paoletti LC, Kasper DL, Michon F, DiFabio J, Jennings HJ, Tosteson TD, Wessels MR. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates. J Clin Invest 1992; 89:203-9.
28. Snedecor GW, Cochran WG. Variance test for homogeniety of the binomial distribution. Statistical Methods. Ames: Iowa State University Press 1967; 240-1.
29. Sokal RR, Rohlf FJ. Bartlett's test for homogeniety of variances. Biometry. San Francisco: W.H. Freeman and Co 1969:370-1.
30. Snedecor GW, Cochran WG. Variance test for homogeniety of the binomial distribution. Statistical Methods. Ames: Iowa State University Press 1967; 258-75.
31. Dunnett C. A multiple comparison procedure for comparing several treatments with a control. J America Stat Assoc 1955; 50:1096-129.
32. Sokal RR, Rohlf FJ. Kruskal-Wallis Test. Biometry. San Francisco: W.H. Freeman and Co 1969; 388-9.
33. Dunn OJ. Multiple comparisons using rank sums. Technometrics 1964; 6:241-52.
34. Siegel S. Nonparametric statistics for the behavioral sciences. New York: MaGraw-Hill 1956; 96-104.